ProQR Therapeutics Files 6-K with Results Announcement
Ticker: PRQR · Form: 6-K · Filed: Mar 13, 2025 · CIK: 1612940
| Field | Detail |
|---|---|
| Company | Proqr Therapeutics N.V. (PRQR) |
| Form Type | 6-K |
| Filed Date | Mar 13, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: results, disclosure, foreign-private-issuer
TL;DR
ProQR Therapeutics dropped a 6-K on 3/13/25 with results, check it out.
AI Summary
ProQR Therapeutics N.V. filed a Form 6-K on March 13, 2025, to furnish a press release dated the same day. This press release announces the company's results, though the specific results are not detailed in the provided text.
Why It Matters
This filing indicates ProQR Therapeutics is providing an update on its performance, which could impact investor understanding of the company's current standing.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of results and does not contain significant new financial or strategic information that would immediately alter risk.
Key Players & Entities
- ProQR Therapeutics N.V. (company) — Filer of the 6-K
- March 13, 2025 (date) — Date of the 6-K filing and press release
FAQ
What specific results are announced in the press release furnished with this 6-K?
The provided text states that Exhibit 99.1 is a press release announcing the Company's results, but the specific details of these results are not included in the excerpt.
What is the filing date of this Form 6-K?
The Form 6-K was filed on March 13, 2025.
What is the principal executive office address of ProQR Therapeutics N.V.?
The principal executive offices are located at Zernikedreef 9, 2333 CK Leiden, The Netherlands.
Is ProQR Therapeutics N.V. required to file annual reports under Form 20-F or Form 40-F?
The filing indicates that ProQR Therapeutics N.V. files annual reports under Form 20-F.
What is the Commission File Number for ProQR Therapeutics N.V.?
The Commission File Number for ProQR Therapeutics N.V. is 001-36622.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 13, 2025 regarding ProQR Therapeutics N.V. (PRQR).